Introduction {#sec1}
============

Functional plasticity within cells of the innate and adaptive immune system increases the breadth of response to pathogens while also limiting responses detrimental to the host. CD4^+^ T cells diversify into distinct effector subsets upon antigenic stimulation. Cytokines and other microenvironmental factors present during T-cell priming direct differentiation via induction of lineage specifying transcription factors (TFs): T-bet is the "master" regulator for T helper 1 (Th1) cells, RORγt for Th17 cells, and GATA3 directs the Th2 program. In vivo, the presence of cells that express TFs and cytokines from opposing Th lineages indicates flexibility between those subsets. Late-stage developmental plasticity is potentially perilous: interferon-γ (IFN-γ^+^) Th17 cells have been implicated in several human autoimmune diseases including inflammatory bowel disease ([@bib1]), juvenile idiopathic arthritis ([@bib20]), and multiple sclerosis ([@bib15]); ex-Foxp3^+^ Th17 cells play a pathogenic role in rheumatoid arthritis ([@bib17]); and interleukin-17 (IL-17^+^) Th2 cells have been positively linked to the severity of asthma ([@bib12]). Elucidating the developmental pathways for these hybrid cells and identifying the factors that regulate Th-cell stability are therefore of critical importance.

Initial lineage specification is driven by cytokines, which activate signal transducer and activator and transcription (STAT) proteins: expression of T-bet is driven by IFN-γ-STAT1 and IL-12-STAT4 ([@bib26]); RORγt by STAT3 downstream of IL-6, IL-21, and IL-23 ([@bib36]). Less is known about the molecular mechanisms that sustain lineage identity. Epigenetic modifications stabilize gene expression and as such, are thought to play a key role in the maintenance of cell-fate commitment. However, the factors that co-ordinate chromatin changes with evolving TF networks in differentiating Th cells are not fully defined. One candidate is the vitamin A metabolite, retinoic acid (RA). RA is known to play a key role in directing the lineage fate of hematopoietic stem cells ([@bib4]), dendritic cells (DCs) ([@bib16]), innate lymphoid cells (ILCs) ([@bib27]), and CD4^+^ T cells ([@bib24]) through activation of the nuclear RA receptor (RAR). In addition to its classical role as a transcriptional regulator, recent studies in embryonic stem cells have identified RA-RAR as an epigenetic regulator ([@bib14; @bib29]). RA synthesis is dynamically controlled at sites of T-cell priming during inflammation, where RA signaling on T cells has been demonstrated ([@bib2; @bib22]). These studies suggest a potential role for RA in Th-cell plasticity. Indeed, RA is critical for Th1-cell immunity ([@bib9; @bib22]) and RA has also been implicated in Th17-cell differentiation where its impact appears to be dose dependent: physiological concentrations of RA enhance Th17-cell differentiation in vitro ([@bib28]), yet administration of higher concentrations of RA both in vitro and in vivo negatively regulates Th17-cell responses ([@bib18; @bib28; @bib33]). Although RARα has been identified as the critical mediator of RA actions in CD4^+^ T cells ([@bib9]), to date a comprehensive analysis of the transcriptional targets of RARα in CD4^+^ T cells has not been reported and the mechanism by which RA regulates these distinct Th-cell fates remains unresolved.

Here we show that RA-RARα is critical for maintenance of the Th1-cell lineage. Loss of RA signaling in Th1 cells resulted in the emergence of hybrid Th1-Th17 and Th17 effector cells. Global analysis of RARα binding and enhancer mapping revealed that RA-RARα directly regulated enhancer activity at Th1-cell-lineage-defining genes while repressing genes that regulate Th17-cell fate. In the absence of RA signaling, infectious and oral antigen induced inflammation resulted in impaired Th1-cell responses with deviation toward a Th17-cell phenotype. These findings identify RA-RARα as a key regulatory node that acts to sustain the Th1-cell response while repressing Th17-cell fate.

Results {#sec2}
=======

RA-RARα Regulates the Balance between Th1 and Th17 Cells {#sec2.1}
--------------------------------------------------------

To directly assess the role of RA in Th-cell differentiation in vivo we used mice carrying a sequence encoding a dominant-negative form of the RA receptor RARα (RARα403) targeted to ROSA26 downstream of a *lox*P-flanked "stop" (lsl) cassette. As shown previously ([@bib22]), interbreeding with mice expressing Cre recombinase from the *Cd4* promoter generates *Cd4*^*cre*^dn*Rara*^*lsl/lsl*^ progeny (dn*Rara* mice) in which RA signaling is abrogated within the T-cell compartment. In contrast to *Rara*^−/−^ mice, expression of this dnRARα disrupts the RA dependent activity of RARα while retaining the ligand independent effects, allowing the specific analysis of RA-dependent functions.

To investigate the role of RA in the generation of Th-cell subsets under steady-state conditions, we determined the expression of cytokines within CD4^+^ T cells with an activated CD44^hi^ phenotype. Examination of the peripheral CD4^+^ T-cell compartment revealed equivalent frequencies and absolute numbers of CD44^hi^CD62^lo^CD4^+^ memory cells in 8-week-old dn*Rara* mice and in Cre^−^, wild-type (WT), littermate controls ([Figures 1](#fig1){ref-type="fig"}A--1C). dn*Rara* effector cells displayed reduced production of IFN-γ compared to their WT counterparts with a \>5-fold increase in the frequency of IL-17^+^ cells ([Figures 1](#fig1){ref-type="fig"}D and 1E). Examination of transcripts for the signature lineage-determining TFs showed reduced mRNA expression of *Tbx21* and significantly higher expression of *Rorc* in dn*Rara* effector CD4^+^ T cells ([Figure 1](#fig1){ref-type="fig"}F). Loss of RA signaling had no impact on Th2 effectors with equivalent levels of *Gata3* expression between dn*Rara* and WT mice ([Figure 1](#fig1){ref-type="fig"}F) and similar frequencies of IL-4 producing CD4^+^ T cells (data not shown).

The frequency and numbers of Foxp3^+^ T cells in the periphery and thymus of dn*Rara* mice were similar to control mice ([Figures S1](#app3){ref-type="sec"}A and S1B), indicating that the increase in Th17 cells was not a consequence of reciprocal regulation by RA of Foxp3^+^CD4^+^ T cells and Th17 cells ([@bib18]). Therefore it is likely that under steady-state conditions RA is critical for differentiation of Th1 cells, while also limiting the differentiation of Th17 cells.

RA Promotes Th1-Cell Differentiation and Inhibits Development of Th17 Cells from Th1 Cell Precursors {#sec2.2}
----------------------------------------------------------------------------------------------------

We considered two alternative explanations of why dn*Rara* mice exhibit reduced memory effector Th1 cells, in parallel with enhanced Th17 cells. The first possibility was that RA is required for the development of Th1 cells while independently suppressing the primary differentiation of Th17 cells. The alternative possibility was that RA is critical in restraining conversion of Th1 cells to Th17 cells. In order to resolve these two possibilities, naive CD4^+^ T cells were differentiated in the presence of Th1 or Th17 polarizing cytokines. dn*Rara* expressing CD4^+^ T cells differentiated under Th1 cell conditions showed a markedly reduced capacity for IFN-γ production ([Figure 2](#fig2){ref-type="fig"}A). Diminished cytokine production was not a consequence of impaired proliferative responses as naive CD4^+^ T cells differentiated under Th1-cell conditions showed robust proliferation, equivalent to WT cells ([Figure S2](#app3){ref-type="sec"}A). In addition, upregulation of the activation markers CD25 and CD44 indicated that dn*Rara* T cells were not impaired in their ability to differentiate into effector cells ([Figure S2](#app3){ref-type="sec"}B). Analysis of TF expression showed that ablating RA signaling resulted in a dramatic reduction in the expression of T-bet in CD4^+^ T cells differentiated under Th1-cell conditions ([Figure 2](#fig2){ref-type="fig"}B). Strikingly, a substantial proportion of dn*Rara* Th1 cells expressed RORγt and co-expression of T-bet and RORγt was observed at the single-cell level. Although we did not observe intracellular IL-17A in cells following brief stimulation with phorbol myristate (PMA) and ionomycin, analysis of supernatants from Th1 polarized cells, reactivated on day 6 of culture on anti-CD3 and anti-CD28 coated plates for 24 hr in non-polarizing media, showed increased expression of IL-17A alongside other Th17-cell-associated cytokines (IL-21 and IL-22) ([Figure 2](#fig2){ref-type="fig"}C). Furthermore, mRNA analysis of dn*Rara* Th1 polarized cells revealed dramatic increases in expression of key signature Th17-cell genes ([Figure 2](#fig2){ref-type="fig"}D). Notably, these Th1 cells displayed the hallmarks of pathogenic Th17 cells with high amounts of *Il23r* expression but reduced amounts of IL-10 mRNA and protein ([Figures 2](#fig2){ref-type="fig"}C and 2D) ([@bib3]).

In order to assess whether enhanced Th17 responses were a general feature of CD4^+^ T cells in which RA signaling is disrupted, naive CD4^+^ T cells from dn*Rara* mice were differentiated under Th17 polarizing conditions. In contrast to our observations above, we did not observe an increase in the frequency of IL-17^+^ cells in dn*Rara* mice during primary differentiation into Th17 cells ([Figure S2](#app3){ref-type="sec"}C), suggesting that RA restrains Th17-cell differentiation only in the context of a Th1 polarizing cytokine milieu. In support of this, RORγt expression was not observed in dn*Rara* expressing naive CD4^+^ T cells differentiated under Th0 or Th2 conditions ([Figure S2](#app3){ref-type="sec"}D).

The simultaneous expression of RORγt and T-bet in dn*Rara* Th1 cells suggested that RA-RARα might act to constrain the deviation of Th1 committed cells toward the Th17-cell lineage. To determine whether the RORγt^+^ cells represented a distinct T-cell population that arose directly from naive CD4^+^ T cells or from previously committed Th1 cells, we interbred *Ifng*^*e*YFP^ (Great) reporter mice with the dn*Rara* mice to allow the tracking of IFN-γ^+^ cells. Naive CD4^+^ T cells from dn*Rara-Ifng*^eYFP^ or littermate control mice were activated under Th1 polarizing conditions. On day 7 of culture, eYFP^+^ (IFN-γ^+^) cells were FACS sorted and underwent genome-wide expression analysis. Key signature Th17-cell genes, including Th17-cell cytokines and receptors for cytokines that promote Th17-cell differentiation (*Il17f*, *Il21*, *Il1r1*, *Il6ra*, and *Il23r*), were highly expressed in dn*Rara* IFN-γ expressing cells relative to WT mice, confirming a hybrid Th1-Th17-cell phenotype ([Figure 2](#fig2){ref-type="fig"}E). Of note, these Th1-Th17 cells retained high expression of *Il12rb2* and *Cxcr3* mRNA, equivalent to WT Th1 cells, while also expressing *Il23r* ([Figure S2](#app3){ref-type="sec"}E). Genes associated with the Th2-cell subset such as *Gata3* and *Il4* were also dysregulated in dn*Rara* Th1 cells consistent with a role for T-bet in repression of GATA3 ([@bib37]). These findings show that, in the absence of RA signaling, committed Th1-cell precursors can give rise to cells with a Th17-cell expression signature providing a new perspective on the origins of Th1-Th17 cells. Collectively, these data demonstrate that RA is not only required for Th1-cell differentiation but is also critical in suppressing Th17-cell development in Th1 polarized cells.

RA-RARα Is Required for Late-Phase, STAT4-Dependent T-bet Expression in Th1 Cells {#sec2.3}
---------------------------------------------------------------------------------

Early expression of T-bet following TCR activation is dependent on IFN-γ, whereas late expression of T-bet (post-termination of TCR signaling) has been shown to be dependent on IL-12 ([@bib26]). To distinguish a requirement for RA signaling in Th1-cell commitment from maintenance of Th1-cell fate, we examined the kinetics of T-bet expression in naive CD4^+^ T cells cultured under Th1 polarizing conditions. Induction of T-bet was observed with comparable amounts of T-bet expression between WT and dn*Rara* T cells at day 3 of culture, indicating that RA-RARα signaling is not required for early Th1 lineage commitment ([Figure 3](#fig3){ref-type="fig"}A). However, T-bet expression was not sustained in dn*Rara* Th1 cells, with substantially diminished expression of T-bet by day 5 of culture. Given that IFN-γ promotes T-bet expression, the expression of T-bet was examined in the presence of recombinant IFN-γ, in order to avoid potential indirect effects caused by reduced IFN-γ production in dn*Rara* Th1 cells. Exogenous IFN-γ enhanced early T-bet expression in both dn*Rara* and WT Th1 cells but did not rescue the late (\>72 hr) impairment in T-bet expression ([Figure 3](#fig3){ref-type="fig"}A). IFN-γ signaling, as measured by STAT1 phosphorylation, was not impaired at either time point (data not shown).

The late IL-12-dependent peak of T-bet expression observed in the presence of blocking IFN-γ antibodies was abrogated in dn*Rara* Th1-cell polarized cells ([Figure 3](#fig3){ref-type="fig"}A) suggesting impaired STAT4 activity. At day 3 of culture, comparable amounts of phosphorylated STAT4 (pSTAT4) were observed between dn*Rara* and WT mice. By contrast, at day 6 of culture, IL-12 induced pSTAT4 was markedly impaired in dn*Rara* T cells ([Figure 3](#fig3){ref-type="fig"}B) despite comparable expression of IL-12Rβ2 mRNA and protein expression and increased expression of *Il12rb1* mRNA ([Figure 3](#fig3){ref-type="fig"}C and 3D). Analysis of *Stat4* expression, demonstrated impaired induction of *Stat4* in the absence of RA signaling ([Figure 3](#fig3){ref-type="fig"}E) with reduced amounts of total STAT4 protein ([Figure 3](#fig3){ref-type="fig"}F). These findings suggest that the observed reduction in pSTAT4 in dn*Rara* Th1 cells is a consequence of diminished STAT4 expression. Consistent with deviation toward the Th17-cell lineage, we observed enhanced pSTAT3 activity in Th1-cell polarized dn*Rara* cells with an increased ratio of pSTAT3/pSTAT4 ([Figures S3](#app3){ref-type="sec"}A and S3B).

To evaluate whether the impairment in T-bet and STAT4 expression correlated with changes in IFN-γ, the time course of IFN-γ expression following initiation of Th1-cell polarization was analyzed in naive dn*Rara-Ifng*^eYFP^ expressing CD4^+^ T cells. The kinetics of IFN-γ induction, as measured by frequency of eYFP^+^ cells, closely mirrored WT cells during the first 72 hr of culture but expression was not sustained in the absence of RA signaling ([Figure 3](#fig3){ref-type="fig"}G). Collectively, these data show that RA plays a temporal role in Th1 differentiation, maintaining Th1-cell commitment through regulation of T-bet and STAT4.

RA-RARα Regulates Th1-Cell Plasticity {#sec2.4}
-------------------------------------

Alterations in the stable expression of lineage-determining TFs are thought to underlie Th-cell stability or plasticity. The emergence of Th1-Th17 cells together with the loss of T-bet expression, suggested a role for RA in the regulation of Th1-cell plasticity. However, diminished T-bet and STAT4 activity from day 3 of primary Th1-cell differentiation prevented assessment of lineage stability in fully differentiated Th1 cells. To determine whether RA-RARα was required for long-term Th1-cell fate, we differentiated naive CD4^+^ T cells from dn*Rara*^lsl/lsl^ mice under Th1-cell conditions, treated them with TAT-Cre ([@bib31]) on days 5 and 7, and restimulated them under Th1-cell conditions for a further 5 days. The temporal loss of RA signaling in Th1 cells resulted in decreased T-bet expression with a reciprocal increase in RORγt expression ([Figure 4](#fig4){ref-type="fig"}A). ∼50% of cells expressed RORγt, which suggests that ongoing RA-RARα activity is critical for sustaining T-bet and suppressing Th17-cell fate. Alterations in the lineage determining TFs did not impact on the cytokine phenotype ([Figure S4](#app3){ref-type="sec"}A). This might in part reflect T-bet independent regulation of the *Ifng* locus at late stages in Th1-cell development.

To further examine the role of RA in Th1-cell stability, naive CD4^+^ T cells from *Ifng*^eYFP^ mice were differentiated under Th1-cell polarizing conditions. eYFP^+^ (IFN-γ^+^) cells were FACS-sorted on day 7 of culture and restimulated under Th1-cell conditions in the presence of the RAR inhibitor LE540 (RAi) or vehicle control (Veh). Inhibition of RA signaling in fully committed Th1 cells propagated for a further 5 days under Th1 conditions resulted in downregulation of T-bet and the emergence of cells co-expressing RORγt ([Figure 4](#fig4){ref-type="fig"}B). Diminished T-bet expression was associated with modest reductions in IFN-γ expression ([Figure S4](#app3){ref-type="sec"}B). Taken together, these data establish that loss of RA signaling in fully committed Th1 cells leads to transdifferentiation to progeny with features of the Th17 lineage and support a model where RA constrains late-stage plasticity of Th1 cells.

RA-RARα Regulates Enhancer Activity at Lineage Determining Th1-Cell Genes {#sec2.5}
-------------------------------------------------------------------------

To better understand the molecular mechanism by which RARα regulates Th-cell fate, we performed genome-wide analysis of RARα binding in WT Th1 cells by ChIP-Seq, combined with transcriptional profiling of dn*Rara*-expressing Th1 cells in order to identify functional targets of RARα. Selected loci were validated by ChIP-qPCR. RARα binding was identified at 1,766 sites in 1,567 genes. RARα binding was detected at 10.3% (76 of 740 genes) of genes downregulated in the absence of RA signaling ([Table S2](#app3){ref-type="sec"}) (hereafter referred to as positively regulated) and 4.8% (56 of 1,169) of the upregulated genes ([Table S3](#app3){ref-type="sec"}). In keeping with its classical role as a positive regulator of transcriptional activation there was significant enrichment of RARα binding at genes positively regulated by RA (Fisher's exact test, p \< 0.0001). However, the presence of RARα at a subset of the negatively regulated genes indicates that RA-RARα also plays a role in transcriptional repression within Th1 cells.

RA-RARα-dependent loci included Th1-cell lineage-defining genes (*Tbx21* and *Stat4-Stat1*). In addition to targeting the *Tbx21* promoter ([Figures 5](#fig5){ref-type="fig"}A and 5B), modest RARα binding was observed at the conserved T-bet enhancer element, 12kb upstream of the transcriptional start site (TSS) ([@bib34]). This was confirmed by ChIP-qPCR ([Figure 5](#fig5){ref-type="fig"}B). Intergenic RARα was also detected at the *Stat4-Stat1* locus and an *Ifng* enhancer element ([Figures S5](#app3){ref-type="sec"}A and S5B).

RA binding to nuclear RARα results in recruitment of co-activator complexes containing the histone acetyl-transferases p300 and CBP ([@bib13]). p300 is highly enriched at enhancer regions where it acetylates H3K27, a marker of active enhancers ([@bib23]), suggesting a possible role for RA-RARα in regulating enhancer activity. To test this, we mapped genome-wide binding of p300, H3K4me1, H3K4me3, and H3K27ac histone modifications in dn*Rara* and WT Th1-cells, validating selected regions by ChIP q-PCR. Active enhancers were operationally defined as regions with increased intensity of H3K4me1, p300, and H3K27ac with low or absent H3K4me3 ([@bib23]).

RARα binding at the *Tbx21*, *Stat4*, and *Ifng* loci co-localized with p300 binding at enhancer regions ([Figures 5](#fig5){ref-type="fig"}A and [S5](#app3){ref-type="sec"}A). dnRARα lacks the activation function 2 (AF2) domain which is required for RA-dependent recruitment of coactivators. Consistent with this, dn*Rara* expressing T cells exhibited a significant reduction in p300 occupancy and H3K27ac deposition at the *Tbx21* enhancer, supporting the direct regulation of enhancer activity by RA-RARα ([Figures 5](#fig5){ref-type="fig"}A and 5C). p300 binding at the *Ifng* and putative *Stat4* intergenic enhancers was also dependent on RA-RARα ([Figures S5](#app3){ref-type="sec"}A and S5C). Loss of p300 binding at the *Stat4-Stat1* intergenic enhancer in *dnRara* Th1 cells correlated with reduced *Stat4* transcripts, whereas *Stat1* expression was actually increased, suggesting that this enhancer element regulated *Stat4* transcription. A recent study identified a role for STAT4 in the regulation of Th1 enhancers ([@bib30]). Given that STAT4 expression was reduced in dn*Rara* Th1 cells, it was possible that the loss of p300 was in part due to reduced expression of STAT4. To address this issue, we assessed the binding of STAT4 in WT Th1 cells and compared p300 occupancy in WT and *Stat4*^*--/--*^ Th1 cells using publicly available ChIP-seq data ([Table S1](#app3){ref-type="sec"}) ([@bib30; @bib32]). Although STAT4 binding was observed at the *Tbx21* enhancer, loss of STAT4 was not associated with obvious differences in p300 binding ([Figure S5](#app3){ref-type="sec"}D), arguing for a direct contribution of RARα to p300 recruitment and enhancer activity. Collectively, these data show that RA regulates expression of key Th1-cell lineage genes through remodeling of enhancer regions.

RA-RARα Represses Th17-Cell Fate in Th1 Cells through Direct Regulation of Th17-Cell Genes {#sec2.6}
------------------------------------------------------------------------------------------

The earlier finding that Th1 cells acquired features of Th17 cells in the absence of RA signaling led us to evaluate direct regulation of Th17-cell-instructing genes by RA-RARα. We first investigated effects of RA on the Th17-cell pioneer factors BATF and IRF4. As previously reported ([@bib3]), these genes were expressed in WT Th1 cells. Strikingly, kinetic analysis of *Batf* and *Irf4* expression in naive cells stimulated under Th1-cell conditions revealed dramatic upregulation of IRF4 (40- to 60-fold) during the initial phase of Th1-cell polarization with comparable expression between dn*Rara* and WT cells ([Figure 5](#fig5){ref-type="fig"}D). Loss of RA signaling resulted in derepression of BATF-IRF4 target genes, *Rorc*, *Il23r*, *Il22*, *Il21*, and *Il12rb1* ([Figure 5](#fig5){ref-type="fig"}E). This suggested that "balancing" factors must be induced in an RA-dependent manner to restrict the actions of BATF-IRF4 complexes at Th17-cell genes. IRF8, an alternative binding partner for BATF, previously shown to suppress Th17 differentiation ([@bib21]), was one of the RARα target genes most suppressed in dn*Rara* Th1 cells. In WT Th1 cells, induction of *Irf*8 expression paralleled *Irf4* expression. However, in dnRara cells *Irf8* expression was not sustained past 24 hr ([Figure 5](#fig5){ref-type="fig"}D). RARα bound at a putative upstream enhancer ([Figures 5](#fig5){ref-type="fig"}F and 5G) and in the absence of RA signaling, reduced p300 and H3K27ac were observed at this locus ([Figure 5](#fig5){ref-type="fig"}H and 5I). Together, these data show that RA directly regulates expression of IRF8 in Th1 differentiating cells and suggests a potential mechanism by which BATF-IRF4 activity is constrained within early Th1 cells.

Transcriptional activation of BATF-IRF4 target genes is dependent on STAT3 and RORγt ([@bib6]). Various genes for cytokines and cytokine receptors associated with STAT3 activation (*Il21*, *Il1r1*, *Il6ra*, and *Il23r*) were derepressed in dn*Rara* Th1 cells ([Figure 5](#fig5){ref-type="fig"}E). RARα targeted the promoter and an upstream enhancer in the *Il6ra* locus ([Figure 5](#fig5){ref-type="fig"}G) with increased H3k27ac observed at the enhancer element in dn*Rara* Th1 cells ([Figure 5](#fig5){ref-type="fig"}J). Consistent with this, dn*Rara* Th1 cells failed to downregulate mRNA and cell-surface IL6-Rα expression during Th1 polarization ([Figures S5](#app3){ref-type="sec"}E and S5F). These findings suggest that RA regulates Th1-cell plasticity in part by inhibiting responsiveness to IL-6.

RORγt was not a direct target of RARα. However, disruption of RA signaling resulted in increased expression of *Runx1*, a TF associated with transactivation of *Rorc* ([Figure S5](#app3){ref-type="sec"}E) ([@bib35]). ChIP analysis confirmed direct regulation of short and long *Runx1* isoform promoters by RA-RARα ([Figure 5](#fig5){ref-type="fig"}G). In Th1 cells, the *Rorc* locus is epigenetically silenced by T-bet ([@bib19]). However, in dn*Rara* cells, the repressive H3K27me3 mark was reduced at RORγt isoform-specific exon ([Figure 5](#fig5){ref-type="fig"}K), consistent with loss of T-bet. These findings suggest that increased RORγt expression in the absence of RARα signaling is in part due to increased accessibility of the *Rorc* locus, with unrestrained activation by Runx1. Collectively these data indicate that RA-RARα antagonises the activity of the core Th17-cell instructing TFs (IRF4, BATF, STAT3, and RORγt), both directly and indirectly, to suppress the Th17-cell gene program. Notably, Th2-cell-associated genes were not identified as targets of RARα ([Tables S2](#app3){ref-type="sec"} and [S3](#app3){ref-type="sec"}) suggesting that direct repression of alternative cell fates by RA-RARα is specific to the Th17-cell program.

Th1-like Th17 Cells Emerge during Infection with *L. monocytogenes* in the Absence of RA Signaling {#sec2.7}
--------------------------------------------------------------------------------------------------

To assess the significance of these findings for immune responses in vivo, we intravenously infected WT and dn*Rara* mice with an attenuated strain of *L. monocytogenes* (ΔActA), Lm-2W, which allows tracking of CD4^+^ T cells specific for listeriolysin O peptide LLO~190--201~ (LLOp). At the peak of the response, CD4^+^ T cells were isolated from the spleen and LLOp antigen-specific T cells were assayed for expression of cytokines and the TFs, T-bet, and RORγt. dn*Rara* mice mounted an effector-T-cell response of similar magnitude to WT mice with comparable frequencies and total numbers of CD44^hi^LLOp:I-A^b^-specific CD4^+^ T cells ([Figures 6](#fig6){ref-type="fig"}A and 6B). In WT mice, Lm-2W induced a Th1-cell restricted response, as evidenced by high T-bet expression within the LLOp-specific T-cell fraction ([Figure 6](#fig6){ref-type="fig"}C). LLOp:I-A^b+^ CD4+ T cells from dn*Rara* mice expressed lower amounts of T-bet and a substantial proportion expressed RORγt, with co-expression of these TFs observed in a subset of cells ([Figure 6](#fig6){ref-type="fig"}C). At day 7 post-infection, a significant proportion of CD4^+^ T cells isolated from the spleen of dn*Rara* mice were IL-17^+^ or dual IL-17A^+^IFN-γ^+^ with a trend toward reduced frequency of IFN-γ^+^ cells ([Figure 6](#fig6){ref-type="fig"}D). Measurement of cytokine protein concentrations from splenocytes restimulated with LLOp confirmed reduced amounts of IFN-γ and concomitant increase in IL-17A ([Figure S6](#app3){ref-type="sec"}A). We did not detect IL-4 production by intracellular staining or protein secretion ([Figure S6](#app3){ref-type="sec"}A and S6B). Consistent with our in vitro data showing downregulation of IL6-Rα on WT Th1 cells, cell-surface IL-6Rα was not detectable on WT LLOp:I-A^b+^ CD4^+^ T cells. However, dn*Rara* LLOp:I-A^b+^ CD4^+^ T cells retained expression of IL-6Rα ([Figure S6](#app3){ref-type="sec"}C), supporting a potential role for IL-6 signaling in the regulation of Th1-cell plasticity. These findings establish that RA-RARα signaling in T cells constrains the emergence of Th17 cells in a Th1-cell-instructing microenvironment in vivo.

RA Regulates the Th1-Th17-Cell Axis in the Gut and Prevents the Development of Intestinal Inflammation {#sec2.8}
------------------------------------------------------------------------------------------------------

RA is constitutively synthesized by a subset of DCs in the gut. To address the physiological importance of RA signaling in the regulation of pathogenic intestinal CD4^+^ T cells, we interbred dn*Rara* mice with OTII mice that transgenically express an ovalbumin (OVA)-specific TCR and transferred naive CD4^+^ T cells from OTII(dn*Rara*) or WT OTII mice into *Rag1*^−/−^ hosts. Recipients were maintained on an OVA-containing diet for 7 days to induce differentiation within the transferred cells and migration to the intestinal tissue. Consistent with the infection experiments, feeding OTII(dn*Rara*)-recipient mice OVA resulted in a shift in the Th1-Th17-cell balance with a deficiency in IFN-γ-producing cells and increased frequency of IL-17^+^ and dual IFN-γ^+^IL-17^+^ cells in the mesenteric lymph node (MLN), lamina propria lymphocytes (LPL), and spleen (Sp), 7 days after transfer ([Figures 7](#fig7){ref-type="fig"}B and 7C). To address the functional significance of the dysregulated cytokine response in dn*Rara* T cells, we orally challenged mice with OVA and evaluated them for development of intestinal inflammation and diarrhea ([Figure 7](#fig7){ref-type="fig"}A). Recipients of OTII(dn*Rara*) cells developed accelerated wasting disease relative to mice that received WT OTII cells ([Figure 7](#fig7){ref-type="fig"}D). Whereas all of the recipients of OTII(dn*Rara*) cells developed severe diarrhea by day 12 ([Figure 7](#fig7){ref-type="fig"}E), recipients of WT cells remained diarrhea free. Cytokine production was also assessed after the first gavage and confirmed an increased frequency of IL-17^+^ cells with concomitant reduction in IFN-γ^+^ cells. Notably, enhanced IL-17 responses were not a consequence of impaired Foxp3^+^ conversion ([Figure 7](#fig7){ref-type="fig"}F). Homing of transferred cells to the gut was not affected in this model with similar frequencies of CD4^+^ T cells detected in the gut tissues ([Figure S7](#app3){ref-type="sec"}A). We conclude that loss of RA signaling leads to deviation from Th1 to Th17 phenotype both in the periphery and the gut where these Th17 cells are associated with significant intestinal inflammation.

Discussion {#sec3}
==========

Dysregulated Th-cell responses underlie the pathogenesis of autoimmune and allergic disease. In contrast to T regulatory (Treg) cells and Th17 cells, the Th1-cell lineage is thought to be relatively stable. However, the factors that control maintenance of the Th1-cell lineage were not previously known. This study identifies RA-RARα as a central regulatory node in the transcriptional network governing Th1-cell stability. We found that RA-RARα directly sustained the expression of lineage determining Th1-cell-associated genes during naive T-cell differentiation while also repressing signature Th17-cell-associated genes. Ablation of RA signaling in Th1-committed cells resulted in enhanced Th1-cell plasticity with deviation towards a Th17-cell phenotype. Using ChIP-seq to identify regulatory elements, we found that RARα bound at enhancers and recruitment of p300 to these regions was dependent on RA signaling. In vivo, both Th17 and Th1-Th17 cells emerged during infection with *L. monocytogenes* and in a model of oral tolerance. In the latter, their presence was associated with significant pathology.

Enhancers play a key role in directing cell fate through the regulation of lineage specifying genes. Enhancer profiling in WT and dn*Rara* T cells revealed RA-dependent activation of enhancers at genes critical for Th1 identity (*Tbx21*, *Stat4*, *Ifng*, and *Irf8*). RA-dependent changes in p300 and H3K27ac were reflected at the transcriptional level suggesting that, in addition to its classical role as a transcriptional regulator, RA regulates gene expression in an enhancer-dependent manner. Although the ability of RA-RARα to target p300-CBP complexes to nucleosomes is well established, regulation of enhancers by RA has not been widely studied. We propose that unliganded RARα at enhancer elements acts as a gatekeeper, enabling initiation of enhancer activation once T cells sense RA in the microenvironment. A similar role has been demonstrated for STAT proteins ([@bib30]), suggesting that environmental cues act as checkpoints for initiation of enhancer activation and T-cell fate. Although H3K4me1 modifications are present at early time points during T-cell differentiation, conversion to "active" status requires acquisition of H3K27ac, which is often not evident until later stages of differentiation ([@bib11]). Consistent with a temporal role for enhancers in maintenance of gene expression, RA signaling was not required for initiation of transcription of target genes but rather acted to maintain their expression. These data highlight the importance of enhancers in maintenance of cell identity and plasticity. It is possible that RA-RARα regulation of enhancers represent the major mechanism by which RA regulates cell fate. A recent study identified enrichment of RARα at enhancers in embryonic stem cells ([@bib5]). Given that the RA-RARα axis is a highly conserved signaling pathway, which plays a critical role in regulating cell-fate specification during embryogenesis and cell differentiation, it will be important to evaluate a broader role for RA-RARα in regulation of enhancer functionality, both in alternative Th-cell subsets and outside of the immune system.

In addition to sustaining expression of Th1-cell-associated genes, we found that RA actively silences genes implicated in Th17-cell differentiation. Among genes known to regulate the Th17-cell program, *Runx1* and *Il6ra* were directly repressed by RA-RARα. In addition, BATF-IRF4 target genes were derepressed in the absence of RA signaling. In Th17 cells, BATF-IRF4 complexes act co-operatively as pioneer factors at key Th17 genes ([@bib6]), modulating chromatin accessibility to facilitate binding of STAT3 and RORγt. On the basis of their expression in alternative Th-cell subsets, it has been suggested that BATF-IRF4 complexes play a universal role in establishing binding of lineage-specific TFs ([@bib6]). However, BATF deficiency does not impact on Th1-cell differentiation ([@bib25]). An alternative model is that upregulation of BATF and IRF4 confers plasticity in early Th1 cells, poising chromatin specifically at Th17-cell-associated genes. IRF8, an alternative binding partner for BATF, negatively regulates Th17-cell differentiation ([@bib21]). Our results identified IRF8 as a member of the Th1-cell transcriptional network whose expression was critically dependent on RA signaling. Induction of IRF8 would be expected to limit plasticity of Th1 cells by repressing Th17 differentiation, potentially by competing for binding to BATF. In support of a role for IRF8 in regulation of Th1-Th17 axis, patients with mutations in IRF8 have impaired Th1 responses ([@bib10]) and single nucleotide polymorphisms (SNPs) in *Irf8* are associated with several autoimmune diseases in which IFN-γ^+^ Th17 cells play a pathogenic role ([@bib8; @bib7]). It will be of interest to identify transcriptional targets of BATF, IRF4, and IRF8 in Th1 cells.

RA signaling was critical to maintain appropriate Th1-cell responses and suppress the development of IL-17^+^ and IFN-γ^+^IL17^+^ cells. Hybrid Th1-Th17 cells are implicated in the pathogenesis of several autoimmune diseases. Their development has been attributed to the plasticity of Th17 cells. Our findings suggest that these cells might alternatively reflect Th1 plasticity and suggest a novel developmental pathway for Th17 cells. Th1 derived "Th17" cells expressed high levels of the receptor for IL-23, a critical determinant of Th17 pathogenicity ([@bib3]), and were associated with significant gut inflammation and pathology in a model of oral tolerance. Further experiments are required to test the prediction that pathogenic Th17 and IFN-γ^+^IL-17^+^ cells which arise in autoimmunity emerge from Th1 cells when RA is deficient or its signaling perturbed.

A range of inflammatory stimuli can induce RA synthesis and signaling during the course of an immune response. Our results suggest that in a Th1-cell instructing microenvironment the dominant action of RA is to repress Th17-cell fate and promote Th1-cell responses. We did not observe enhanced Th17-cell responses during primary Th17-cell differentiation, suggesting that the impact of RA on T-cell stability might vary both temporally and among tissues. Previously we have shown in a model of skin allograft rejection that impaired Th1 responses in dn*Rara* mice were accompanied by increased Th2-cell cytokines ([@bib22]). We did not identify direct repression of Th2-cell-associated genes by RARα. However, T-bet suppresses GATA3 ([@bib37]) and in the presence of a Th2 skewing micro-environment, such as the skin, impaired expression of T-bet in the absence of RA signaling renders cells susceptible to Th2 deviation. Thus, the effects of RA on T-cell fate are likely dependent on external and intrinsic factors that shape T-cell polarity.

In summary, we show that RA signaling plays a critical role in regulating stability and functional plasticity of Th1 cells. Regulation of enhancer activity at lineage determining genes by RA-RARα provides mechanistic evidence for reciprocal regulation of Th1 and Th17-cell programs. In the absence of RA signaling, downmodulation of T-bet, STAT4, and IFN-γ, and loss of repression of Th17-cell genes, creates a permissive environment for transdifferentiation of Th1 cells to Th17 cells. This study identifies the RA-RARα axis as a potential node for intervention in diseases in which dysregulation of the Th1-Th17-cell axis is observed.

Experimental Procedures {#sec4}
=======================

Mice {#sec4.1}
----

C57Bl/6 dn*Rara* mice have been described previously ([@bib22]). *Ifng*^eYFP^ (GREAT) mice were purchased from the Jackson Laboratory. Mice were bred and maintained at Charles River Laboratory, UK, in pathogen-free conditions. All animal experiments were conducted in accordance with the UK Animals (Scientific Procedures) Act 1986. C57Bl/6 OTII(dn*Rara*), OTII, and *Rag1*^*−/−*^ mice were bred and maintained at the Rockefeller University specific pathogen-free animal facility.

Cell Isolation, Cell Culture, and Flow Cytometry {#sec4.2}
------------------------------------------------

Sort purified, naive CD4^+^CD25^--^CD44^lo^CD62L^hi^ T cells were cultured with T-cell depleted splenocytes (APCs) and anti-CD3 under polarization conditions for Th0, Th1, Th2, and Th17-cell-associated subsets. Details are provided in the [Supplemental Experimental Procedures](#app3){ref-type="sec"}. For analysis of cytokine production, cells were restimulated with 100 ng/ml phorbol 12-myristate 13-acetate (PMA) and 500 ng/ml ionomycin in the presence of monensin for 4--5 hr at 37°C. Cells were stained with LIVE/DEAD Dead Cell Stain (Invitrogen), followed by staining for cell-surface markers and then fixed and permeabilized (BD Biosciences) for staining of intracellular antigens. Flow cytometry was performed on a LSR Fortessa (BD Biosciences) and analyzed with Flowjo software (Tree Star).

TAT-Cre Transduction {#sec4.3}
--------------------

Sort purified naive CD4^+^ T cells were differentiated under Th1 conditions. After 5 days, cells were treated with 50 μg/ml TAT-Cre peptide for 45 min at 37°C, then washed and expanded in IL-2-containing medium. After 48 hr cells were retreated with Tat-Cre followed by polarization under Th1 conditions.

Real-Time Quantitative PCR {#sec4.4}
--------------------------

Total RNA was extracted from cells with RNeasy Mini kit (QIAGEN) and cDNA was synthesized with Qscript RT kit (Quanta). Quantitative gene-expression analysis was performed using Taqman primer probe sets (Applied Biosystems), listed in [Table S4](#app3){ref-type="sec"}. Expression of target genes was normalized to β-actin.

Microarray Gene-Expression Profiling {#sec4.5}
------------------------------------

For gene-expression analysis Affymetrix (for *Ifng*^eYFP^ dataset) or Agilent (for the dn*Rara* Th1 dataset) microarray chips were used. Differentially expressed genes were detected using fold-change and t test analysis. See [Supplemental Experimental Procedures](#app3){ref-type="sec"} for further information.

Chromatin Immunoprecipitation and ChIP-Seq {#sec4.6}
------------------------------------------

Immunoprecipitation and DNA sequencing was performed by Active Motif. The following antibodies were used: anti-H3K27me3 (Millipore 07--449), anti-p300 (Santa Cruz sc--551X), anti-H3K4me1 (Active Motif 39287), anti-H3K4me3 (Active Motive 39159), anti-H3K27ac (active Motif 39133), anti-RARα (Diagenode C15310155). Illumina sequencing libraries were prepared from the ChIP and Input DNAs. For ChIP q-PCR, enrichment calculated as binding events per 1,000 cells using Active Motif's normalization scheme. Detailed methods for ChIP-seq and binding site analyses are provided in the [Supplemental Information](#app3){ref-type="sec"}.

*L. monocytogenes* Infection {#sec4.7}
----------------------------

Mice were infected i.v. with 1 × 10^6^ cfu *L. monocytogenes* and spleens were harvested 7 days later. Splenocytes were enriched for CD4^+^ T cells with a CD4^+^ T-cell negative selection microbead kit (Miltenyi Biotec) and stained with PE labeled, LLO:I-A^b^ dextramer (Immudex) and cell-surface antibodies. For analysis of intracellular cytokine production, splenocytes were restimulated with LLO peptide (PiProteomics) at 10 μg/ml for 6 hr.

Food-Antigen-Induced Diarrhea Model {#sec4.8}
-----------------------------------

Naive CD4^+^ T cells from OTII or OTII(dn*Rara*) were intravenously transferred to Rag1^−/−^ mice. These mice were then maintained on a diet containing OVA for 7 days and challenged with oral OVA on days 9 and 10. Lymphocytes were isolated from the intestinal epithelium, lamina propria, MLN, and spleen at the indicated time points after the start of oral OVA exposure of the recipient mice. Detailed experimental procedures are described in the [Supplemental Experimental Procedures](#app3){ref-type="sec"}.

Statistical Analysis {#sec4.9}
--------------------

Statistical significance was calculated by unpaired two-tailed Student's t test with Graphpad Prism software. p values \< 0.05 were considered significant. p values are denoted in figures as follows: ^∗^, p \< 0.05; ^∗∗^, p \< 0.01; ^∗∗∗^, p \< 0.001; ^∗∗∗∗^, p \< 0.0001.
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![RA Controls the Balance between Th1 and Th17 Effector Cells\
(A) Splenic CD4^+^ T cells from dn*Rara* and WT littermate control mice. Numbers indicate percentage CD62L^lo^CD44^hi^ cells (top left) or CD62L^hi^CD44^lo^ T cells (bottom right) gated on CD4^+^ cells.\
(B) Frequency and total number (C) of CD62L^lo^CD44^hi^ in the CD4^+^ T-cell population in WT and dn*Rara* mice (n = 3 or 4 per group).\
(D) Intracellular IFN-γ and IL-17A expression in splenic CD4^+^CD44^hi^ T cells after stimulation with phorbol 12-myristate 13-acetate (PMA) and ionoymycin.\
(E) Statistical data from cells as in (D).\
(F) Quantitative real-time PCR analysis of *Tbx21*, *Rorc*, and *Gata3* in splenic CD4^+^CD62^lo^CD44^hi^ cells (as in 1A), sorted by flow cytometry.\
Data are from two or three independent experiments with similar results. Mean ± SEM, ^∗^p \< 0.05; ^∗∗∗∗^p \< 0.0001\
See also [Figure S1](#app3){ref-type="sec"}.](gr1){#fig1}

![RA Signaling Required for Th1-Cell Differentiation and Repression of Th17-cell Fate in Th1-Cell Precursors\
Sorted naive CD4+ T cells from dn*Rara* or WT mice were cultured under Th1 conditions for 6 days.\
(A) Intracellular expression of IFN-γ and IL-17A following stimulation with PMA and ionomycin.\
(B) T-bet and RORγt expression. Grey histograms indicate staining for *Tbx21*^--/--^ (left panel) or isotype control antibody (right panel). Numbers show MFI. Numbers in quadrants represent percent cells in each.\
C) Amount of IL-17A, IL-21, IL-22, and IL-10 in supernatants following restimulation of cells as in (A) with α-CD3 and α-CD28 for 24 hr as measured by multiplex bead array. Triplicate culture wells.\
(D) Quantitative real time PCR analysis of Th1 and Th17-cell signature cytokine and TF genes following stimulation with PMA and ionomycin.\
(E) Naive CD4^+^ T cells from dn*Rara-Ifng*^eYFP^ and *Ifng*^eYFP^ mice were cultured under Th1 conditions. IFN-γ (eYFP^+^) cells were sorted on day 7 following stimulation with PMA and ionomycin. Heatmaps displaying the fold changes of genes that were differentially expressed (fold change \> 1.5, p \< 0.05) for selected cytokines or cytokine receptors (upper panel) and TFs (lower panel). Samples from three independent experiments.\
Representative data of at least three (A and B) or two (C and D) independent experiments. Mean ± SEM.\
See also [Figure S2](#app3){ref-type="sec"}.](gr2){#fig2}

![RA Required for Late Phase T-bet Expression\
(A) Naive CD4^+^ T cells from dn*Rara* and WT mice were differentiated under Th1 conditions with combinations of IFN-γ or IFN-γ antibody. T-bet expression analyzed at the indicated time points. Histograms gated on CD4^+^ T cells.\
(B) Flow cytometric analysis of STAT4 phosphorylation in naive CD4^+^ T cells from dn*Rara* and WT mice differentiated under Th1 conditions. Cells analyzed directly from culture after 3 days (left panel) or on day 6 following treatment with (solid lines) or without (dashed lines) 25 ng/ml IL-12 for 30 min (right panel). Shaded histogram displays pSTAT4 staining in cells cultured under Th0 conditions.\
(C) Cell-surface expression of IL-12Rβ2 on day 6 of culture.\
(D) Quantitative real-time PCR analysis of *Il12rb1 and Il12rb2* on day 6.\
(E) Quantitative real-time PCR analysis of *Stat4* in Th1 polarized cells at indicated time points. Expression relative to naive CD4^+^ T cells.\
(F) Western blot analysis of total STAT4 protein on day 6 of Th1 culture.\
(G) Naive CD4^+^ T cells from dn*Rara-Ifng*^eYFP^ and control mice were activated under Th1 conditions. Frequency of IFN-γ^+^ (eYFP^+^) cells at indicated time points, gated on viable CD4^+^.\
Data representative of two to three independent experiments. Mean ± SEM.\
See also [Figure S3](#app3){ref-type="sec"}.](gr3){#fig3}

![Loss of RA Signaling in Fully Committed Th1 Cells Leads to Th1 Plasticity and Divergence Toward the Th17 Lineage\
(A) Naive CD4^+^ T cells from dn*Rara*^*lsl/lsl*^ mice were differentiated under Th1 conditions. Th1 cells were transduced with TAT-Cre on days 5 and 7 and repolarized under Th1 conditions for a further 5 days. Intracellular expression of T-bet and RORγt.\
(B) Naive CD4^+^ T cells from *Ifng*^eYFP^ mice were differentiated under Th1 conditions. IFN-γ (eYFP^+^) cells were sorted on day 7 and restimulated under Th1 conditions for 5 days in the presence of Veh or RAi. Intracellular expression of T-bet and RORγt.\
Data representative of two independent experiments.\
See also [Figure S4](#app3){ref-type="sec"}.](gr4){#fig4}

![RA-RARα Regulates Enhancer Activity at Th1 Lineage Associated Loci and Represses Th17 Genes\
Naive CD4^+^ T cells from WT and dn*Rara* mice were cultured for 6 days under Th1 conditions prior to chromatin precipitation and transcriptional profiling.\
(A) ChIP-seq binding tracks at *Tbx21* locus for RARα in WT Th1 cells and p300 binding, H3K27ac, H3K4me1, and H3K4me3 modifications in WT and dn*Rara* Th1 cells.\
(B) Validation of the RARα-binding regions in WT Th1 cells by ChIP-qPCR. Untr6 region serves as a negative control. Binding events per 1,000 cells displayed as "Enrichment."\
(C) The effects of dn*Rara* expression on p300 and H3k27ac abundance at the Tbx21 locus were validated by ChIP-qPCR.\
(D) Quantitative real-time PCR analysis of *Batf*, *Irf4*, and *Irf8* mRNA in naive CD4^+^ T cells from dn*Rara* or WT cells differentiated under Th1-cell conditions for 0, 24, 48, 72 hr. Mean ± SEM, replicate wells.\
(E) Log2 values of fold changes in gene expression as measured by microarray analyses. Average fold change depicted.\
(F) ChIP-seq binding tracks at *Irf8* locus for cells as in (A).\
(G) Validation of RARα ChIP-seq regions by ChIP-qPCR.\
(H--J) ChIP analysis of p300 and H3K27ac at selected loci.\
(K) ChIP analysis of H3K27me3 at the RORc locus. *Actb* locus serves as a negative control.\
Data from three independent experiments (E) or representative of two independent experiments (B--D, G--K); Mean ± SD unless noted otherwise. Abbreviation: pro, promoter.\
See also [Figure S5](#app3){ref-type="sec"}.](gr5){#fig5}

![RA Signaling Required to Prevent the Generation of Th17 Cells during Infection with *L. monocytogenes*\
(A) Frequency of LLOp:I-A^b^ CD4^+^ T cells isolated from spleen of dn*Rara* and WT mice 7 days after infection with an attenuated strain of *L. monocytogenes* (Lm-2W). Gated on CD4^+^ T cells.\
(B) Absolute numbers of LLOp:I-A^b^ CD4^+^ T cells as in (A).\
(C) Intracellular T-bet and RORγt expression gated on LLOp:I-A^b^ CD4^+^ T cells.\
(D) Intracellular staining for IFN-γ and IL-17A following stimulation of splenocytes with LLOp for 6 hr, 7 days after infection with Lm-2W. Gated on CD4^+^ T cells. Right panel shows statistical data pooled from three independent experiments (3--6 mice per group).\
Representative data of at least three (A and B), or two independent experiments (C). Mean ± SEM.\
See also [Figure S6](#app3){ref-type="sec"}.](gr6){#fig6}

![Loss of RA Signaling Causes Dysregulated Th1 and Th17 Response and Increased Pathogenicity in a Model of Gut Inflammation\
(A) Schematic illustration of the adoptive transfer experiment.\
(B) Intracellular expression of IL-17A and IFN-γ among CD4^+^ cells from the spleen (Sp), mesenteric lymph nodes (MLN), and lymphocytes from the lamina propria (LPL) of mice as in (A) 7 days after transfer.\
(C) Statistical data for frequency of IFN-γ^+^, IL-17^+^, and IFN-γ^+^IL-17^+^ cells as in (B) in MLN and Sp.\
(D) Percentile change of original body weight in *Rag1*^*−/−*^ recipients treated as in (A) (n = 5--7 per group). Mean ± SD.\
(E) Frequency of diarrhea-free mice among *Rag1*^*−/−*^ recipients as in (A) (OTII recipients n = 3, OT-II(dn*Rara*) recipients n = 5).\
(F) Frequencies of IL-17, IFN-γ, and Foxp3 in CD4^+^ cells isolated from Sp, MLN, LPL, and IELs of mice as in (A), 9 days after transfer (n = 5 or 6 per group).\
Data from one experiment (B and C), pooled from two independent experiments (D and F), or representative of two independent experiments (E). Mean ± SEM unless otherwise noted.](gr7){#fig7}
